Samba Scientific’s Post

Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. Highlights: - Uncover the hurdles of patient referrals and manufacturing regulations, amplifying the complexity of these therapies. - Explore essential commercialization strategies and infrastructure needs while balancing innovation with necessity. -Learn about navigating regulatory scrutiny and stakeholder management for safer, more accessible therapies. What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications? #cellculture #processdevelopment #bioprocessing #celltherapymanufacturing #cellandgenetherapy #leadbiotech

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

“We’re in a constrained supply environment. We just can’t physically treat enough patients with cell and gene therapies.” Jason C. Foster Last week at ISCT, we unveiled IRO®, our next-generation manufacturing platform. In an interview with Endpoints News, our CEO Jason C. Foster shared how IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a seamless transition from R&D into the clinic, and from clinical scale to commercial scale. By empowering scientists with tools that Automate Better Biology™ and accelerate product development, we are working to help enable widespread patient access and scale the impact of life-changing cell and gene therapies. Read more ➡️ https://lnkd.in/epRnmgnE #IRO #TheNewStandard #AccelerateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications?

🔬 Early-Phase Testing Support: From Discovery to the Clinic 🧬 At #DINAMIQS, we recognize that while the genome and capsid are closely linked, it’s precision in #genomeengineering that truly unlocks the full therapeutic potential of gene therapies. Our science-driven approach goes beyond just the vector—we’re here to help you harness the full power of your gene therapy programs. Recent conversations point to growing demand for more tailored solutions during early-phase testing: #constructdesign, #optimization, #feasibility, and #DOE studies. With the capability of performing small-scale runs (starting at 0.5L) to help you quickly assess and select your top asset(s) for clinical advancement and future #scalablemanufacturing, we provide these tailored early-phase solutions that others may not—because we know expertise and adaptability are key to your success. #GeneTherapy #ViralVector #AAV #Lenti #EarlyPhaseTesting #Biotech #Innovation #Optimization #Commercialization

Cell and gene therapies are at a pivot point. These breakthrough therapies show big promise, but the business models that support these new advances are racing to catch up with the science. Can we keep up the pace in the current climate? This webinar convenes a series of expert sessions where you can hear from the researchers, investors, and business leaders at the forefront of the industry. Find out the latest strategy behind moving the next generation of advances for patients forward. #medicalaffairs #medaff #webinar #genetherapy

Rethinking ecosystems to enable access https://lnkd.in/etktvGiz Cell and gene therapy in the Asia-Pacific region. This update includes insights for overcoming the challenges of affordability and navigating healthcare systems in the Asia-Pacific region, especially in resource-constrained markets. It also explains why public-private partnerships and policy-shaping are key in building a future with optimal access to transformative cell and gene therapies in the region. https://lnkd.in/etktvGiz #HEOR #MarketAccess #WeAreAvalereHealth

🌟 Transforming Healthcare with Cell & Gene Therapies 🌟 Recently, I posted a series of 13 articles about cell and gene therapies. I have collated them into a comprehensive booklet, "Transforming Healthcare: Navigating Challenges and Opportunities in Cell and Gene Therapy"! This resource dives deep into 13 critical topics shaping the future of cell and gene therapies, offering actionable insights for industry leaders and decision-makers. From tackling regulatory hurdles and optimizing manufacturing to ensuring patient access and addressing ethical considerations, this booklet is packed with strategies and innovations driving progress in the field. Whether you're navigating market trends, enhancing sustainability, or exploring partnerships, there's something valuable here for everyone. 💡 Let's shape the future of healthcare together! Click the link below to access the booklet and share your thoughts. #CellTherapy #GeneTherapy #HealthcareInnovation #BiotechLeadership #FutureOfMedicine #CellandGeneTherapy #CGT

🧬#DYK how many gene therapy clinical trials are being conducted globally? According to Alliance for Regenerative Medicine, there are more than 620 clinical trials of gene therapies being carried out across the world as of Q3 of this year. As investigative gene therapies continue to increase, manufacturing becomes more and more critical to ensuring product safety and efficacy. Learn more about our proprietary #AAV manufacturing process that minimizes impurities and consistently generates industry-leading functional full capsid ratios and process yields: https://ampgtx.com/. #genetherapy #cdmo #manufacturing #processdevelopment #analyticaldevelopment